Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13495473 | 0.86 | GPR119 (0.68) | MAPTTP53SMN1; SMN2GPR119MEN1 | |
| SCHEMBL3716352 | 0.85 | MAPT (0.60) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6711588 | 0.85 | TP53 (0.60) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2512100 | 0.83 | MAPT (0.69) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6707734 | 0.81 | MAPT (0.61) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2898573 | 0.79 | CPT1A (0.62) | MAPTTP53SMN1; SMN2GPR119 | |
| SCHEMBL10186983 | 0.79 | MEN1 (0.69) | MAPTTP53MEN1KMT2A | |
| SCHEMBL29336848 | 0.78 | MAPT (0.66) | MAPTTP53 | |
| SCHEMBL3552794 | 0.78 | MEN1 (0.58) | MAPTTP53MEN1KMT2A | |
| SCHEMBL6352106 | 0.78 | MEN1 (0.58) | MAPTTP53SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | disclosed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | MAPT 4753/4885TP53 2308/4885SMN1; SMN2 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.